Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 23 Jan 2023
The EMA validated regulatory application for arpraziquantel, a potential treatment for schistosomiasis in pre-school aged children
23 January 2023 - Arpraziquantel is the first investigational drug in regulatory phase amongst the different projects supported by the Global ...
Posted by Michael Wonder on 23 Jan 2023
Brukinsa (zanubrutinib) receives marketing authorisation for chronic lymphocytic leukaemia and marginal zone lymphoma in Great Britain by MHRA
19 January 2023 - Brukinsa is the only treatment authorised for marginal zone lymphoma in Great Britain ...
Posted by Michael Wonder on 23 Jan 2023
TGA grants provisional approval to Pfizer’s COVID-19 bivalent (Comirnaty Original/Omicron BA.4-5 COVID-19 vaccine) booster dose vaccine
23 January 2023 - On 20 January 2023, the TGA granted provisional approval to Pfizer’s bivalent COVID-19 vaccine: tozinameran and famtozinameran ...
Posted by Michael Wonder on 23 Jan 2023
TGA commences evaluation of Moderna COVID-19 vaccine (Spikevax) for potential transition to full registration
20 January 2023 - The TGA has commenced evaluation of an application from Moderna to transition its COVID-19 vaccine, Spikevax, ...
Posted by Michael Wonder on 23 Jan 2023
China’s drug pricing policy impedes biotech profits
23 January 2023 - Beijing’s push to boost the sector has been undermined by reimbursement rules. ...
Posted by Michael Wonder on 23 Jan 2023
RenalGuard Therapy receives FDA breakthrough device designation for prevention of cardiac surgery associated AKI
20 January 2023 - CardioRenal Systems announced today that the FDA granted breakthrough device designation for its RenalGuard Therapy device ...
Posted by Michael Wonder on 23 Jan 2023
Mum's push for cystic fibrosis treatment to be subsidised for children under 12
23 January 2023 - Mila was diagnosed with cystic fibrosis aged just one, after experiencing lung failure in hospital, and ...
Posted by Michael Wonder on 22 Jan 2023
DualityBio announces DB-1303 granted fast track designation by the US FDA for the treatment of advanced, recurrent or metastatic endometrial carcinoma with HER2 overexpression
20 January 2023 - Duality Biologics announced that the US FDA has granted fast track designation to DB-1303 for the treatment ...
Posted by Michael Wonder on 22 Jan 2023
Pharmaceuticals campaigner moving to Australia after drug she desperately needs for spinal muscular atrophy is only funded for under 18s
22 January 2023 - This week, PHARMAC announced it was looking to fund a second drug to treat the neurological ...
Posted by Michael Wonder on 21 Jan 2023
Sources of innovation in gene therapies - approaches to achieving affordable prices
21 January 2023 - Gene therapies are a fast growing area of innovation and potentially hold great promise for clinical care. ...
Posted by Michael Wonder on 21 Jan 2023
RemeGen announces two indications for anti-HER2 antibody drug conjugate disitamab vedotin included in China's National Reimbursement Drug List for 2023
20 January 2023 - RemeGen is pleased to announce that as of 18 January 2023, two indications for the Company's ...
Posted by Michael Wonder on 21 Jan 2023
Novartis warns US plan to curb drug prices could hit key research
21 January 2023 - US Government plans to rein in drug prices could discourage work in some of Novartis' most ...
Posted by Michael Wonder on 21 Jan 2023
China's first and only approved third generation BCR-ABL inhibitor olverembatinib included into the 2022 National Reimbursement Drug List
18 January 2023 - Ascentage Pharma and Innovent Biologics today announced that the novel drug olverembatinib has been included into the ...
Posted by Michael Wonder on 21 Jan 2023
Assessing and extending California’s insulin manufacturing initiative
19 January 2023 - Set against the backdrop of current debates about lowering drug costs, lowering the price of insulin—a lifesaving ...
Posted by Michael Wonder on 21 Jan 2023
For only the second time, a big drug maker offers a warranty on a medicine
19 January 2023 - In a bid to blunt competition and address rising drug costs, Sanofi is offering a warranty ...